OSI: Tarceva Sales Strong, Data Due This Year In Bid For Wider Label
This article was originally published in The Pink Sheet Daily
Executive Summary
SATURN should provide more clues on KRAS as efficacy biomarker, CEO says.
You may also be interested in...
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction
Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small lung cancer